Obinutuzumab, Acalabrutinib, and Venetoclax After Optional Debulking With Bendamustine in Relapsed/Refractory CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
Lancet Haematol 2022 Aug 18;[EPub Ahead of Print], P Cramer, M Fürstenau, S Robrecht, A Giza, C Zhang, AM Fink, K Fischer, P Langerbeins, O Al-Sawaf, E Tausch, C Schneider, J Schetelig, P Dreger, S Böttcher, KA Kreuzer, A Schilhabel, M Ritgen, M Brüggemann, M Kneba, S Stilgenbauer, B Eichhorst, M HallekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.